Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Marginal Zone Lymphoma
Interventions: Pirtobrutinib, Rituximab; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 2
States / cities: St Louis, Missouri • Salt Lake City, Utah

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Nicotine Replacement, Questionnaire Administration, Vaping; Drug · Other · Device
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Migrainous Headache
Interventions: Metoclopramide, Placebo; Drug · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years to 18 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cutaneous Ulcer, Diabetic Ulcer, Surgical Wound Dehiscence, Burns - Multiple, Pressure Ulcers, Mixed Ulcer, Ischemic Ulcer
Interventions: MTX-001 (Dermacyte Liquid); Drug
Lead sponsor: Merakris Therapeutics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Arvada, Colorado

Conditions: Primary Immune Deficiency
Interventions: Human Normal Immunoglobulin for Subcutaneous Administration; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 13
States / cities: Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 9 more

Conditions: Vascular Access Complications
Interventions: AccuCath IV Catheter System, Conventional IV Catheter System; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Wound Heal
Interventions: WOUNDCHEK Bacterial Status; Device
Lead sponsor: Woundchek Laboratories BV; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Seroma
Interventions: doxycycline, No intervention; Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV)
Interventions: Perianal and Digital Anorectal Exam, Cervical Swabs, Anal Swabs, High Resolution Anoscopy (HRA); Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Product B® IsaGenesis®, IsaGenesis®; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Sickle Cell Disease, Thalassemia
Interventions: Hydroxyurea, Hydroxyurea Oral Capsule; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 9 Months to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Sarcoma,Soft Tissue
Interventions: 2% intranasal mupirocin ointment, 4% chlorhexidine gluconate body cleanser; Drug
Lead sponsor: Adam Olson; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bladder Cancer, Cystectomy
Interventions: Exercise Training, Nutritional Intervention; Other · Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Urethral Obstruction
Interventions: Fetal Cystoscopy, Fetal vesicoamniotic shunt; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 16 Weeks to 26 Weeks · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Adult Females
Interventions: GSK1349572 (dolutegravir); Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cerebral Edema, Saline Solution, Hypertonic
Interventions: 3% Sodium Chloride, 23.4% Sodium Chloride, 8.4% Sodium Bicarbonate; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Primary Open Angle Glaucoma (POAG)
Interventions: CyPass Micro-Stent, Cataract Surgery; Device · Procedure
Lead sponsor: Alcon Research; Industry
Eligibility: 45 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Glendale, Arizona • Fayetteville, Arkansas • La Jolla, California + 19 more

Conditions: Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
Interventions: HDM201, MBG453, Venetoclax; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Prevention, Injection Drug Use
Interventions: Mail delivery of at-home self-administered HIV tests; Diagnostic Test
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Asthma
Interventions: GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS); Biological · Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,717 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 119
States / cities: Birmingham, Alabama • Scottsboro, Alabama • Litchfield Park, Arizona + 94 more

Conditions: Pancreatic Cancer, Malnutrition
Interventions: Ensure Max Protein; Dietary Supplement
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cannabis Intoxication
Interventions: Cannabis; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years to 55 Years
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior

Treatment of Acute Migraine Headache in Children

Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

Comparison of AccuCath IV Catheter and Conventional IV Catheter in Interventional Radiology

Performance of WOUNDCHEK Bacterial Status

Doxycycline Versus Standard Care to Prevent Seroma Formation

New Strategies to Assess Anal Cancer Risk In Women

Relative Bioavailability of Two Different Milk Thistle Formulations

Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere

Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)

Patient-Centered Surgical Prehabilitation

First Safety Study in Humans of a Single Dose of CPG 52364

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Fetal Cystoscopy for Lower Urinary Tract Obstruction

GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects

Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation

A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Feasibility of Internet-based HIV Prevention Research

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Whipple Protein Study

The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking